Wierstra Benjamin T, Kadri Sameer, Alomar Soha, Burbano Ximena, Barrisford Glen W, Kao Raymond L C
Division of Internal Medicine, Department of Medicine, University of Calgary, Calgary, AB, Canada.
Harvard School of Public Health, Harvard University, Boston, MA, USA.
Crit Care. 2016 May 6;20(1):122. doi: 10.1186/s13054-016-1291-8.
The optimal timing of initiating renal replacement therapy (RRT) in critical illness complicated by acute kidney injury (AKI) is not clearly established. Trials completed on this topic have been marked by contradictory findings as well as quality and heterogeneity issues. Our goal was to perform a synthesis of the evidence regarding the impact of "early" versus "late" RRT in critically ill patients with AKI, focusing on the highest-quality research on this topic.
A literature search using the PubMed and Embase databases was completed to identify studies involving critically ill adult patients with AKI who received hemodialysis according to "early" versus "late"/"standard" criteria. The highest-quality studies were selected for meta-analysis. The primary outcome of interest was mortality at 1 month (composite of 28- and 30-day mortality). Secondary outcomes evaluated included intensive care unit (ICU) and hospital length of stay (LOS).
Thirty-six studies (seven randomized controlled trials, ten prospective cohorts, and nineteen retrospective cohorts) were identified for detailed evaluation. Nine studies involving 1042 patients were considered to be of high quality and were included for quantitative analysis. No survival advantage was found with "early" RRT among high-quality studies with an OR of 0.665 (95 % CI 0.384-1.153, p = 0.146). Subgroup analysis by reason for ICU admission (surgical/medical) or definition of "early" (time/biochemical) showed no evidence of survival advantage. No significant differences were observed in ICU or hospital LOS among high-quality studies.
Our conclusion based on this evidence synthesis is that "early" initiation of RRT in critical illness complicated by AKI does not improve patient survival or confer reductions in ICU or hospital LOS.
在合并急性肾损伤(AKI)的危重症中,启动肾脏替代治疗(RRT)的最佳时机尚未明确确立。关于该主题的试验结果相互矛盾,且存在质量和异质性问题。我们的目标是综合关于“早期”与“晚期”RRT对合并AKI的危重症患者影响的证据,重点关注该主题的最高质量研究。
通过PubMed和Embase数据库进行文献检索,以识别涉及根据“早期”与“晚期”/“标准”标准接受血液透析的合并AKI的成年危重症患者的研究。选择最高质量的研究进行荟萃分析。感兴趣的主要结局是1个月时的死亡率(28天和30天死亡率的综合)。评估的次要结局包括重症监护病房(ICU)和住院时间(LOS)。
共识别出36项研究(7项随机对照试验、10项前瞻性队列研究和19项回顾性队列研究)进行详细评估。9项涉及1042例患者的研究被认为质量较高,并纳入定量分析。在高质量研究中,“早期”RRT未发现生存优势,OR为0.665(95%CI 0.384-1.153,p = 0.146)。根据ICU入院原因(外科/内科)或“早期”定义(时间/生化)进行的亚组分析未显示出生存优势。在高质量研究中,ICU或住院LOS未观察到显著差异。
基于这一证据综合分析,我们的结论是,在合并AKI的危重症中“早期”启动RRT并不能改善患者生存,也不能缩短ICU或住院时间。